Tibet Pharma, the Associated Company of China Medical System, Acquired the Related Licensed Rights of Sputnik-V vaccine (COVID-19 Adenoviral Vaccines) in Mainland China, Hong Kong, Macao and Taiwan

Company News

On November 11, Tibet Rhodiola Pharmaceutical Holding Co. (“Tibet Pharma”, 600211.SH) announced that it has reached collaboration with Russian LIMITED LIABILITY COMPANY “HUMAN VACCINE” for Sputnik-V vaccine (COVID-19 adenoviral vaccines), and Tibet Pharma obtained the related licensed rights of the vaccine to register, develop, manufacture, import or commercialize the product in mainland China, Hong Kong, Macao and Taiwan, as well as to export the product to designated regions.

About Sputnik V vaccine
The vaccine was developed by the Russia Gamaleya Research Center and was granted registration certificate from Russian Health Ministry in August 2020 after completing Phase I and Phase II clinical trials. Sputnik V clinically adopts a two-step vaccination procedure that inoculates two recombinant adenoviral vectors of different serotypes (AD5-S and AD26-S) respectively. The effectiveness has already been proved and recognized in clinical trials. Based on regulations passed in Russia during the epidemic, the vaccine was approved for use in Russia domestically to prevent COVID-19 infection, and has entered into the stage of commercialization in Russia.

In accordance with Tibet Pharma’s strategy, investing in and acquiring of Russian adenoviral vaccines will enrich Tibet Pharma’s products reserves and further expand its product portfolio, benefiting its long-term development.

For detail of forementioned investment of Tibet Pharma, please refer to its announcement: